Advertisement

Journal of Primary Prevention

, Volume 14, Issue 3, pp 197–207 | Cite as

Smart drugs: Implications of student use

  • R. J. Canterbury
  • E. Lloyd
Articles

Abstract

The use of Smart Drugs to enhance intelligence, improve memory and maximize cognitive functioning in healthy individuals has attracted the attention of the popular press. This paper discusses the implication of the nonmedical college student use of “nootropic” Smart Drugs, a class of pharmaceuticals legally available in other countries to treat diseases associated with mental decline or dysfunction. Nootropic drug use is compared to steroid use in a student population. In a survey of college students, 5% of the males reported casual use of a drug to increase their intelligence, enhance their memory and make them smarter: 2.5% of these students probably used a nootropic drug.

Key words

Smart drugs substance abuse nootropics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allain, H., Boyer, D., Kossman, L., & Lepine, J. P. (1990). Therapeutic target for cognition enhancers: Diagnosis and clinical phenomenology.Pharmacopsychiatry, 23(sup), 65–69.Google Scholar
  2. Alperovitch, A. (1989). Clinical trials in memory disorders: Objectives and methodology.Archives of Gerontology & Geriatrics, 207–214.Google Scholar
  3. Amaducci, L., Angst, J., Beck, P., & Benkert, D. (1992). Consensus conference on the methodology of clinical trials of “nootropics”.Pharmacopsychiatry, 23 171–175.Google Scholar
  4. Anshel, M. (1991). A survey of elite athletes on the perceived causes of using banned drugs in sports.Journal of Sport Behavior, 14 283–310.Google Scholar
  5. Bartus, R. (1990). Drugs to treat age-related neurodegenerative problems: The final frontier of medical science.Journal of the American Geriatrics Society, 38 680–695.Google Scholar
  6. Boffey, P.M. (1988, July 25).The New York Times.Google Scholar
  7. Brady, D. (1992, April 27). Fuel for thought.Maclean's, pp. 60–61.Google Scholar
  8. Buresova, O., & Bures, J. (1976). Piracetam-induced facilitation of interhemispheric transfer of visual information in rates.Psychopharmacologia, 46 93–102.Google Scholar
  9. Bylinsky, G. (1986, January 20). Medicine's next marvel: The memory pill.Fortune, pp. 68–71.Google Scholar
  10. Dean, W., & Morgenthaler, J. (1990). Smart drugs & nutrients: How to improve your memory and increase your intelligence using the latest discoveries in neuroscience. Santa Cruz: B&J Publications.Google Scholar
  11. Erlich, J. (1992, September). Brain gain: Drugs that boost intelligence.Omni, pp. 42–51.Google Scholar
  12. Finally, a drink that makes you smart. (1991, October 14).Newsweek, p. 64.Google Scholar
  13. Foltyn, P., Lucker, P., Schnetker, J., & Wetzelsberger, N. (1983). A test model for cerebrally active drugs as demonstrated by the example of the new substance aniracetam.Arzneimittel-forschung, 33 865–867.Google Scholar
  14. Frostl, W., & Maitre, L. (1989).Pharmacopsychiatry, 22(sup), 54.Google Scholar
  15. Gallai, V., Mazzotta, G., del Gatto, F., & Montesi, S. (1991). A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.Acta Neurologica, 13(1), 1–12.Google Scholar
  16. Gough, D. (1989). Steroids in athletes: Is the edge worth the risk? A review and commentary.Journal of Alcohol and Drug Education, 35 28–34.Google Scholar
  17. Herrmann, W. (1991). Efficacy and clinical relevance of cognition enhancers.Alzheimer Disease & Associated Disorders, 5 7–12.Google Scholar
  18. Hough, R. (1992, October). Get smart (effectiveness of piracetam).Saturday Night, pp. 38–40.Google Scholar
  19. ICN Biomedicals, Inc. (1992–93). (Catalog). Irvine, CA: Author.Google Scholar
  20. Itoh, J., Nakeshima, T., & Kameyama, T. (1990). Utility of an elevated plus-maze for the evaluation of memory in mice: Effects of nootropics, scopalamine and electroconvulsive shock.Psychopharmacology, 101 27–33.Google Scholar
  21. Lamb, D. (1980). Anabolic steroids and strength and power related athletic events.Journal of Physical Education-Recreation, 51 58–59.Google Scholar
  22. LeGro, W. (1992, March/April). Thinking capsules.Men's Health, p. 48.Google Scholar
  23. Lloyd, E., & Pryor, J. (1992). [Virginia Consortium Alcohol and Other Drug Survey]. Unpublished raw data.Google Scholar
  24. Merlini, L., & Pinza, M. (1989). Trends in searching for new cognition enhancing drugs.Progress in Neuro-Psychopharmacology & Biological Psychiatry, 13(sup), 561–575.Google Scholar
  25. Mondadori, C., Bhatnagar, A., Borkowski, J., & Hausler, A. (1990). Involvement of a steroidal component in the mechanism of action of piracetam-like nootropics.Brain Research, 506 101–108.Google Scholar
  26. Mondadori, C., Ducret, T., & Borkowski, J. (1991). How long does “memory consolidation” take? New compounds can improve retention performance, even if administered up to 24 hours after the learning experience.Brain Research, 555 107–111.Google Scholar
  27. Nicholson, C. (1990). Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.Psychopharmacology, 101 147–159.Google Scholar
  28. Olton, D. S., & Wenk, L. (1990). The development of behavioral tests to assess the effects of cognitive enhancers.Pharmacopsychiatry, 23(sup), 49–51.Google Scholar
  29. Orenstein, P. (1992, March). Get smart?Mademoiselle, pp. 164–165.Google Scholar
  30. Purvis, A. (1992, June 8). Ultra think fast.Time, p. 80.Google Scholar
  31. Saleta, B., & Grunberger, J. (1984). The hypoxia model in human psychopharmacology: Neurophysiological and psychometric studies with aniracetam I.V.Human Neurobiology, 3 171–181.Google Scholar
  32. Saleta, B., Grunberger, J. & Linzmayer, L. (1980). Quantitative EEG and psychometric analyses in assessing CNS-activity of R013-5057 — a cerebral insufficiency improver.Methods and Findings in Experimental Clinical Pharmacology, 2 269–285.Google Scholar
  33. Sarter, M., Hagan, J., & Dudchenko, P. (1992). Behavioral screening for cognition enhancers.Psychopharmacology, 7 144–159.Google Scholar
  34. Sheaffer, R. (1992, Summer). Psychic vibrations.Skeptical Inquirer, pp. 364–365.Google Scholar
  35. ‘Smart drugs’ not smart. (1992, May).FDA Consumer, pp. 3–4.Google Scholar
  36. Stewart, D. (1992, May/June). A fast fix for slow thinkers.Health, p. 26.Google Scholar
  37. Tang, C. N., Shi, Q-Y, Katchman, A., & Lynch, G. (1991). Modulation of time course of fast EPSCs and glutamate channel kinetics by aniracetam.Science, 254 288–290.Google Scholar
  38. Wild, R. (1992, March/April). Maximize your brain power.Men's Health, pp. 44–49.Google Scholar
  39. Wilsher, C. R. (1986). Developmental dyslexia and the nootropic concept.Early Child Development and Care, 26 207–228.Google Scholar
  40. Wolf, G. (1991, September 5). Don't get wasted, get smart!Rolling Stone, pp. 59–60.Google Scholar
  41. Yesalis, C., Streit, A., & Vicary, J. (1989). Anabolic steroid use: indications of habituation among adolescents.Journal of Drug Education, 2 103–116.Google Scholar

Copyright information

© Human Sciences Press, Inc. 1994

Authors and Affiliations

  • R. J. Canterbury
    • 2
  • E. Lloyd
    • 1
  1. 1.Department of Psychiatric MedicineUniversity of VirginiaUSA
  2. 2.Institute for Substance Abuse Studies, BRH DivisionUniversity of VirginiaCharlottesville

Personalised recommendations